Prevalence and Prognostic Impact of Sarcopenia Assessed by AI-Based CT Muscle Segmentation and Nutritional Index in Advanced Gastric Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20251214006

Enrollment

237

Registered

2025-12-14

Start date

2025-11-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced gastric cancer Malnutrition Sarcopenia Cancer cachexia Gastric cancer Sarcopenia Body composition Artificial intelligence Computed tomography Prognostic Nutritional Index Nutritional status Survival analysis Thailand

Interventions

Patients diagnosed with advanced gastric adenocarcinoma (unresectable, recurrent, or metastatic) treated or followed at Maharat Nakhon Ratchasima Hospital between January 2018 and December 2023

Supportive Care

Advanced Gastric Cancer

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age 18 years or more 2. Histologically confirmed advanced gastric adenocarcinoma (unresectable, recurrent, or metastatic) 3. Availability of baseline contrast-enhanced abdominal CT including the L3 vertebral level performed within 90 days of diagnosis 4. Availability of laboratory results (serum albumin and lymphocyte count) within 14 days of diagnosis for PNI calculation 5. Documented follow-up data for survival outcome

Exclusion criteria

Exclusion criteria: 1. Incomplete demographic or clinical data (e.g., missing height or weight for SMI calculation) 2. Poor-quality or incomplete CT imaging not suitable for muscle segmentation Missing essential laboratory parameters for PNI computation 3. Presence of another active malignancy within 5 years (except adequately treated in-situ carcinoma or non-melanoma skin cancer) 4. Acute infection or inflammatory condition at time of lab testing that may significantly affect PNI values

Design outcomes

Primary

Measure	Time frame
Prevalence of Sarcopenia Any timepoint Define by SMI	—

Secondary

Measure	Time frame
Association of SMI and Overall survival End of Study Muslce area by CT devide by square of height. / Death status,Association of PNI and Overall survival End of Study PNI is calculated based on Albumin and Lymphocyte count.	—

Countries

Thailand

Contacts

Public ContactJirawat Thanestada

Maharat Nakhon Ratchasima hospital

jthanestada@gmail.com044235870

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026